KR870006923A - 고도로 플루오르화된 유기 화합물의 안정한 유제 - Google Patents

고도로 플루오르화된 유기 화합물의 안정한 유제 Download PDF

Info

Publication number
KR870006923A
KR870006923A KR870000565A KR870000565A KR870006923A KR 870006923 A KR870006923 A KR 870006923A KR 870000565 A KR870000565 A KR 870000565A KR 870000565 A KR870000565 A KR 870000565A KR 870006923 A KR870006923 A KR 870006923A
Authority
KR
South Korea
Prior art keywords
emulsion
highly fluorinated
fluorinated organic
surfactant
organic compound
Prior art date
Application number
KR870000565A
Other languages
English (en)
Inventor
씨. 클라크 2세 레란드
에프. 샤우 로버트
Original Assignee
원본미기재
칠드런스 허스피탈 리서취 파운데이션
헤마겐 피에프씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 칠드런스 허스피탈 리서취 파운데이션, 헤마겐 피에프씨 filed Critical 원본미기재
Publication of KR870006923A publication Critical patent/KR870006923A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Abstract

내용 없음.

Description

고도로 플루오르화된 유기 화합물의 안정한 유제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (24)

  1. 고도로 플루오르화 된 유기화합물; 표면활성이 거의 없고 물에 거의 불용성인 오일; 계면활성제 및 물로 구성된 유제.
  2. 제1항에 있어서, 고도로 플루오르화된 유기 화합물이 머플루오로탄소인 유제.
  3. 제1항에 있어서, 고도로 플루오르화된 유기 화합물이 퍼플루오로데칼린, 퍼플루오로디메틸아다만탄, 퍼플루오로옥틸브로마이드, 퍼플루오로-4-메틸-옥타히드로 퀴놀리디진, 퍼플루오로-N-메틸-데카히드로퀴놀린, F-메틸-1-옥사-데칼린, 퍼플루오로-비시클로(5.3.0)데칸, 퍼플루오로 옥타히드로퀴놀리디진, 퍼플루오로-5,6-디히드로-5-데센, 퍼플루오로인단, 퍼플루오로트리메틸시클로헥산, 퍼플루오로이소프로필시클로헥산 및 퍼플루오로-4,5-디히드로-4옥텐중에서 선택되는 유제.
  4. 제1항 내지 제3항중 어느 한항에 있어서, 상기 유제가 약 115℃에서 약 15분간 가열한 후에 안정한 유제.
  5. 제1항에 있어서, 오일이 유제의 비-고도로 플루오르화된 유기화합물 용적의 약 10 내지 30중량%로 존재하는 유제.
  6. 제5항에 있어서, 오일이 유제의 비-고도로 플루오르화된 유기화합물 용적의 약 15 내지 20중량%로 존재하는 유제.
  7. 제1항에 있어서, 오일이 생리학적으로 허용되는 오일인 유제.
  8. 제1항 또는 제7항에 있어서, 오일이 액체 지방 오일 중에서 선택되는 유제.
  9. 제1항에 있어서, 계면활성제가 유제의 비-고도로 플루오르화된 유기화합물 용적의 약 0.5 내지 7중량%의 양으로 존재하는 유제.
  10. 제9항에 있어서, 계면활성제가 유제의 비-고도로 플루오르화된 유기화합물 용적의 약 1 내지 2중량%의 양으로 존재하는 유제.
  11. 제1항에 있어서, 계면활성제가 생리학적으로 허용되는 계면활성제인 유제.
  12. 제1항 또는 제11항에 있어서, 계면활성제가 레시틴인 유제.
  13. 제1항 또는 제2항에 있어서, 고도로 플루오르화된 유기화합물이 약 75 내지 약 10용적%로 존재하는 유제.
  14. 제13항에 있어서, 고도로 플루오르화된 유기화합물이 약 40용적%로 존재하는 유제.
  15. 제1항에 있어서, 등장제, 삼투압조절제, 혈장확장제 및 산화방지제중 적어도 하나의 화합물을 추가로 함유하는 유제.
  16. 제1항 내지 제15항중 어느 한 항의 유제를 인체의 산소운반 및 전달에 치료학적으로 유효한 양으로 함유하는 적혈구 세포 대용품.
  17. 제1항 내지 제15항중 어느 한 항의 유제를 핵자기 공명, X-선 및 초음파중에서 선택된 장치에 의해 영상화하기 위해 임상적으로 유효한 양으로 함유하는 생물학적 영상화를 위한 콘트라스트제.
  18. 고도로 플루오르화된 유기 화합물을 전부 또는 일부의 계면활성제 및 약간의 물의 존재하에 표면활성이 거의 없으며 물에 거의 불용성인 오일과 혼합하여 첫 번재 유제를 제조하고, 첫 번째 유제, 나머지 물 및 나머지 계면활성제를 유화시켜 최종 유제를 제조하는 단계로 이루어짐을 특징으로 하는, 고도로 플루오르화된 유기화합물; 표면 활성이 거의 없으며, 물에 거의 불용성인 오일; 계면활성제 및 물로 이루어진 유제의 제조방법.
  19. 제18항에 있어서, 최종유제를 약 115℃에서 약 15분간 가열하여 멸균하는 단계를 추가로 함유하며, 이러한 조건하에서도 상기 유제가 안정성을 유지하는 방법.
  20. 필수적으로 퍼플루오로인단으로 구성되는, 기체 또는 증기 색전증을 야기하지 않고 동물 체내로 주입하기 위한 기체 전달제 액상 조성물.
  21. 제20항에 있어서, 산소를 전달하기에 충분한 양의 퍼플루오로인단의 유화된 입자, 비독성, 비-용혈성 양의 유화제 및 물을 함유하는 수성유제로 구성되는 조성물.
  22. 필수적으로 물, 퍼플루오로인단 및 계면활성제로 구성되는, 기체 또는 증기 색전증을 야기하지 않고 사용하기 위한 인공 혈액 액상 조성물.
  23. 필수적으로 제1항 또는 제6항의 조성물로 구성되는, 기체 또는 증기 색전증을 야기하지 않고 동물신체에 사용하기 위한 핵자기공명 콘트라스트제.
  24. 동물 체내 또는 적출 기관내에 제1항 또는 제6항의 조성물을 도입함을 특징으로 하여, 동물 체내 또는 적출 기관에서 산소전달을 후원하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR870000565A 1986-01-24 1987-01-24 고도로 플루오르화된 유기 화합물의 안정한 유제 KR870006923A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US82229186A 1986-01-24 1986-01-24
US822291 1986-01-24
US88371386A 1986-07-09 1986-07-09
US883713 1986-07-09

Publications (1)

Publication Number Publication Date
KR870006923A true KR870006923A (ko) 1987-08-13

Family

ID=27124629

Family Applications (1)

Application Number Title Priority Date Filing Date
KR870000565A KR870006923A (ko) 1986-01-24 1987-01-24 고도로 플루오르화된 유기 화합물의 안정한 유제

Country Status (10)

Country Link
EP (1) EP0231091B1 (ko)
JP (1) JPH0822815B2 (ko)
KR (1) KR870006923A (ko)
CN (1) CN87100492A (ko)
AU (1) AU598226B2 (ko)
CA (1) CA1337969C (ko)
DE (1) DE3785054T2 (ko)
ES (1) ES2054658T3 (ko)
IE (1) IE59175B1 (ko)
IL (1) IL81356A (ko)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077036A (en) * 1986-01-14 1991-12-31 Alliance Pharmaceutical Corp. Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid
US4927623A (en) * 1986-01-14 1990-05-22 Alliance Pharmaceutical Corp. Dissolution of gas in a fluorocarbon liquid
US5080885A (en) * 1986-01-14 1992-01-14 Alliance Pharmaceutical Corp. Brominated perfluorocarbon emulsions for internal animal use for contrast enhancement and oxygen transport
US4865836A (en) * 1986-01-14 1989-09-12 Fluoromed Pharmaceutical, Inc. Brominated perfluorocarbon emulsions for internal animal use for contrast enhancement and oxygen transport
US4781676A (en) * 1987-02-20 1988-11-01 Air Products And Chemicals, Inc. Interstitial administration of perfluorochemical emulsions for reoxygenation of hypoxic tumor cells
US4895876A (en) * 1987-03-20 1990-01-23 Air Products And Chemicals, Inc. Concentrated stable fluorochemical aqueous emulsions containing triglycerides
US4866096A (en) * 1987-03-20 1989-09-12 Air Products And Chemicals, Inc. Stable fluorochemical aqueous emulsions
US5171755A (en) * 1988-04-29 1992-12-15 Hemagen/Pfc Emulsions of highly fluorinated organic compounds
US4996041A (en) * 1988-08-19 1991-02-26 Toshiyuki Arai Method for introducing oxygen-17 into tissue for imaging in a magnetic resonance imaging system
US5114703A (en) * 1989-05-30 1992-05-19 Alliance Pharmaceutical Corp. Percutaneous lymphography using particulate fluorocarbon emulsions
DE68928349T2 (de) * 1989-07-05 1998-05-07 Alliance Pharma Fluorkohlenstoffemulsionen mit gesättigten phospholipidemulgatoren
GB8919929D0 (en) * 1989-09-04 1989-10-18 Nycomed As Compositions
US6088613A (en) 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US6001335A (en) 1989-12-22 1999-12-14 Imarx Pharmaceutical Corp. Contrasting agents for ultrasonic imaging and methods for preparing the same
US5305757A (en) 1989-12-22 1994-04-26 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US6551576B1 (en) 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5352435A (en) * 1989-12-22 1994-10-04 Unger Evan C Ionophore containing liposomes for ultrasound imaging
US5656211A (en) 1989-12-22 1997-08-12 Imarx Pharmaceutical Corp. Apparatus and method for making gas-filled vesicles of optimal size
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5733572A (en) 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5776429A (en) 1989-12-22 1998-07-07 Imarx Pharmaceutical Corp. Method of preparing gas-filled microspheres using a lyophilized lipids
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5469854A (en) 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US6146657A (en) 1989-12-22 2000-11-14 Imarx Pharmaceutical Corp. Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US5705187A (en) 1989-12-22 1998-01-06 Imarx Pharmaceutical Corp. Compositions of lipids and stabilizing materials
US5773024A (en) 1989-12-22 1998-06-30 Imarx Pharmaceutical Corp. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5922304A (en) 1989-12-22 1999-07-13 Imarx Pharmaceutical Corp. Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
DE4100059C2 (de) * 1991-01-03 1994-08-25 Adatomed Pharma & Med Behandlungsflüssigkeit zum Wiederanlegen (Entfalten) abgelöster Netzhaut an die Aderhaut des Auges
US5205290A (en) * 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
US5874062A (en) 1991-04-05 1999-02-23 Imarx Pharmaceutical Corp. Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents
US5146014A (en) * 1991-07-02 1992-09-08 Air Products And Chemicals, Inc. Perfluoroethyldimethyl cyclohexane
FR2679150A1 (fr) * 1991-07-17 1993-01-22 Atta Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations.
DE69230885T3 (de) * 1991-09-17 2008-01-24 Ge Healthcare As Gasförmige ultraschallkontrastmittel
US6723303B1 (en) 1991-09-17 2004-04-20 Amersham Health, As Ultrasound contrast agents including protein stabilized microspheres of perfluoropropane, perfluorobutane or perfluoropentane
US5409688A (en) * 1991-09-17 1995-04-25 Sonus Pharmaceuticals, Inc. Gaseous ultrasound contrast media
MX9205298A (es) * 1991-09-17 1993-05-01 Steven Carl Quay Medios gaseosos de contraste de ultrasonido y metodo para seleccionar gases para usarse como medios de contraste de ultrasonido
US5304325A (en) * 1991-11-13 1994-04-19 Hemagen/Pfc Emulsions containing alkyl- or alkylglycerophosphoryl choline surfactants and methods of use
US5295953A (en) * 1992-05-26 1994-03-22 Hemagen/Pfc Method and apparatus for extracorporeal separation of fluorochemicals from whole blood of a patient
IL108416A (en) 1993-01-25 1998-10-30 Sonus Pharma Inc Colloids with phase difference as contrast ultrasound agents
WO1994016739A1 (en) * 1993-01-25 1994-08-04 Sonus Pharmaceuticals, Inc. Phase shift colloids as ultrasound contrast agents
US5558855A (en) * 1993-01-25 1996-09-24 Sonus Pharmaceuticals Phase shift colloids as ultrasound contrast agents
WO1995003835A1 (en) * 1993-07-30 1995-02-09 Alliance Pharmaceutical Corp. Stabilized microbubble compositions for ultrasound
US5798091A (en) 1993-07-30 1998-08-25 Alliance Pharmaceutical Corp. Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement
DE4405627A1 (de) * 1994-02-22 1995-08-24 Hoechst Ag Fluorkohlenwasserstoffe enthaltende Ölemulsionen
US5502094A (en) * 1994-05-20 1996-03-26 Minnesota Mining And Manufacturing Company Physiologically acceptable emulsions containing perfluorocarbon ether hydrides and methods for use
US5658962A (en) 1994-05-20 1997-08-19 Minnesota Mining And Manufacturing Company Omega-hydrofluoroalkyl ethers, precursor carboxylic acids and derivatives thereof, and their preparation and application
US5736121A (en) 1994-05-23 1998-04-07 Imarx Pharmaceutical Corp. Stabilized homogenous suspensions as computed tomography contrast agents
US5540909A (en) * 1994-09-28 1996-07-30 Alliance Pharmaceutical Corp. Harmonic ultrasound imaging with microbubbles
US6743779B1 (en) 1994-11-29 2004-06-01 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US5830430A (en) 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
US5997898A (en) 1995-06-06 1999-12-07 Imarx Pharmaceutical Corp. Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US6139819A (en) 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
US6033645A (en) 1996-06-19 2000-03-07 Unger; Evan C. Methods for diagnostic imaging by regulating the administration rate of a contrast agent
US5804162A (en) * 1995-06-07 1998-09-08 Alliance Pharmaceutical Corp. Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
US6231834B1 (en) 1995-06-07 2001-05-15 Imarx Pharmaceutical Corp. Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
WO1997025978A1 (fr) * 1996-01-15 1997-07-24 BELOYARTSEV, Arkady Felixovich Procede de production d'emulsions perfluorocarbonees a des fins medicales
US5611344A (en) * 1996-03-05 1997-03-18 Acusphere, Inc. Microencapsulated fluorinated gases for use as imaging agents
HU226714B1 (en) * 1996-03-05 2009-07-28 Acusphere Microencapsulated fluorinated gases for use as imaging agents
DE69736981D1 (de) 1996-05-01 2007-01-04 Imarx Pharmaceutical Corp In vitro verfahren zum einbringen von nukleinsäuren in eine zelle
US5837221A (en) * 1996-07-29 1998-11-17 Acusphere, Inc. Polymer-lipid microencapsulated gases for use as imaging agents
US6414139B1 (en) 1996-09-03 2002-07-02 Imarx Therapeutics, Inc. Silicon amphiphilic compounds and the use thereof
US5846517A (en) 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
ATE231004T1 (de) 1996-09-11 2003-02-15 Imarx Pharmaceutical Corp Verbesserte verfahren zur diagnostischen bilderzeugung unter verwendung eines kontrastmittels und eines vasodilators
US5834519A (en) * 1996-10-11 1998-11-10 Wayne State University Stabilized gas-supersaturated emulsions and suspensions
US6537246B1 (en) 1997-06-18 2003-03-25 Imarx Therapeutics, Inc. Oxygen delivery agents and uses for the same
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6090800A (en) 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6143276A (en) 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
US6416740B1 (en) 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US6548047B1 (en) 1997-09-15 2003-04-15 Bristol-Myers Squibb Medical Imaging, Inc. Thermal preactivation of gaseous precursor filled compositions
US6123923A (en) 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
JP2002527410A (ja) 1998-10-12 2002-08-27 マリンクロッド・インコーポレイテッド 新規超音波造影剤
RU2259819C1 (ru) * 2004-03-01 2005-09-10 Кузнецова Ирина Николаевна Эмульсия перфторорганических соединений медицинского назначения и способ её получения
US8012457B2 (en) 2004-06-04 2011-09-06 Acusphere, Inc. Ultrasound contrast agent dosage formulation
EP2783703A1 (en) 2013-03-25 2014-10-01 B. Braun Melsungen AG Semifluorocarbon compound containing contrast agent
EA201791437A1 (ru) 2014-12-31 2017-12-29 Лантеус Медикал Имэджинг, Инк. Композиции микросфер c инкапсулированным в липиде газом и соответствующие способы
TWI832081B (zh) 2016-05-04 2024-02-11 美商藍瑟斯醫學影像公司 用於形成充氣微球體及成像個體之方法、震盪裝置及電腦可讀軟體
US9789210B1 (en) 2016-07-06 2017-10-17 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents
AU2021393591A1 (en) 2020-12-04 2023-07-06 University Of Tennessee Research Foundation Method for diagnosing amyloid diseases
KR102342324B1 (ko) * 2020-12-11 2021-12-23 애경케미칼주식회사 불소계 계면활성제 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5331209B2 (ko) * 1973-10-05 1978-09-01
US4252827A (en) * 1979-05-23 1981-02-24 The Green Cross Corporation Oxygen-transferable fluorocarbon emulsion
FR2515198A1 (fr) * 1981-10-22 1983-04-29 Centre Nat Rech Scient Microemulsions aqueuses de fluorocarbures indefiniment stables a une temperature donnee, procede d'obtention et application a titre de transporteurs d'oxygene
JPS5924132B2 (ja) * 1980-12-02 1984-06-07 株式会社 林原生物化学研究所 栄養補給用乳剤の製法
JPS58225013A (ja) * 1982-06-25 1983-12-27 Green Cross Corp:The フルオロカ−ボン乳化製剤
CA1187882A (en) * 1981-11-27 1985-05-28 Kazumasa Yokoyama Perfluoro compound and emulsion thereof
US4490351A (en) * 1982-03-15 1984-12-25 Children's Hospital Medical Center Methods of treating disorders of an eye with liquid perfluorocarbons
JPS5967229A (ja) * 1982-10-08 1984-04-16 Green Cross Corp:The 超音波診断造影剤
WO1984003624A1 (en) * 1983-03-17 1984-09-27 University Patents Inc Method for inhibiting the growth of anaerobes
CA1257828A (en) * 1984-04-16 1989-07-25 William Mccormick Perfluoro compound dispersions containing reduced amounts of surfactant and process of preparation
SE8505048L (sv) * 1985-10-25 1987-04-26 Nutritional Int Res Inst Nutritionsemulsion med syretransporterande egenskaper

Also Published As

Publication number Publication date
DE3785054D1 (de) 1993-05-06
AU6796987A (en) 1987-07-30
ES2054658T3 (es) 1994-08-16
CN87100492A (zh) 1987-08-19
JPH0822815B2 (ja) 1996-03-06
IL81356A (en) 1991-09-16
DE3785054T2 (de) 1993-07-08
AU598226B2 (en) 1990-06-21
CA1337969C (en) 1996-01-23
EP0231091A1 (en) 1987-08-05
EP0231091B1 (en) 1993-03-31
JPS62228010A (ja) 1987-10-06
IE59175B1 (en) 1994-01-26
IL81356A0 (en) 1987-08-31
IE870187L (en) 1987-07-24

Similar Documents

Publication Publication Date Title
KR870006923A (ko) 고도로 플루오르화된 유기 화합물의 안정한 유제
KR880010756A (ko) 안정한 퍼플루오로케미칼 에멀죤 용액
KR880010755A (ko) 고농도의 안정한 플루오로케미칼 수화 에멀션
BALLANTYNE JR et al. Silicone fluid: response to massive subcutaneous injections of dimethylpolysiloxane fluid in animals
KR900700085A (ko) 고불화 유기 화합물의 유탁액
EP0091820A1 (en) Artificial blood and other gas transport agents
Gley The Internal Secretions
KR900005973A (ko) 사이클로스포린 안과용 조성물
CH639822A5 (de) Verwendung von spreitenden oelen in pour-on-formulierungen.
SIMKINS Use of massive doses of vitamin A in the treatment of hyperthyroidism
Gramstad et al. Interaction of cyclosporin and its solvent, cremophor, with atracurium and vecuronium
Coble et al. Acute endrin poisoning
Naffziger Progressive Exophthalmos: Hunterian Lecture delivered at the Royal College of Surgeons of England on 17th May 1954
JPS5832829A (ja) 血管造影剤
Smelser Water and fat content of orbital tissues of guinea pigs with experimental exophthalmos produced by extracts of the anterior pituitary gland
US5536753A (en) Stable perfluorocarbon and oil emulsions
HATCHER et al. Transplantation of the entire small bowel in inbred rats using cyclosporine
WEIDMAN et al. Experimental production of paraffin oil tumors in monkeys
GOLDZIRHER et al. Transplantation of adrenal tissue in Addison's disease
Bowker et al. Microanatomy of the intersection of the distal sesamoidean impar ligament and the deep digital flexor tendon: a preliminary report
Bellows et al. Anoxia Cataract.
Fischer Experiences in seeking an ethiodol emulsion for lymphography
Brown et al. Fluosol-DA, a perfluorochemical oxygen-transport fluid for the management of a trochanteric pressure sore in a Jehovah’s Witness
Melville The action of pituitary extract upon the blood pressure of the normal unanesthetized animal and the effects of ephedrine or adrenaline thereupon
Murray et al. A Discussion On The Pathology Of Exophthalmic Goître

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application